American Journal of Cardiovascular Drugs

Articles Available on Medscape

• A Critical Review of the Efficacy and Safety of Inclisiran
  Review current evidence for the use of inclisiran sodium, a novel siRNA, for reducing LDL-C in patients with ASCVD at very high cardiovascular risk.

  November 24, 2021

• Gout Pharmacotherapy in Cardiovascular Diseases
  This review examines the utility of current gout therapies in the treatment and prevention of cardiovascular disease, including allopurinol, febuxostat, and colchicine.

  September 30, 2021

• Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation
  How prevalent is non-adherence to thromboprophylaxis guidelines in AF? This review details the global extent of this problem and explores factors which may influence guideline non-adherence.

  July 26, 2021

• Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels
  Review the use of new and emerging lipid-lowering agents targeted to lowering lipoprotein(a), now recognized as an independent risk factor for premature atherosclerotic disease.

  May 20, 2021

• Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents
  The new classes of glucose-lowering drug have shown beneficial cardiovascular effects, including antihypertensive properties. Review and compare their BP-lowering potential in this paper.

  April 02, 2021

Table of Contents

2021 -

• Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia. 

  February 04, 2021

  • [ MEDLINE Abstract ]
  • [ Full-text from Publisher's Site ]

• Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction. 

  January 13, 2021

  • [ MEDLINE Abstract ]
  • [ Full-text from Publisher's Site ]